Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
An examination of HER2 and NF-κB receptor (RANK) coexpression revealed increased levels of both proteins in aggressive prostate tumors and metastatic deposits.
|
27793843 |
2017 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Previous work in animal models showed that p110α was the key isoform in breast tumors driven by oncogenes, including MT and HER2, while p110β was key in prostate tumors driven by Pten loss.
|
24991009 |
2014 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Both wild-type and mutant forms of plexinB1 are potential targets for anti-cancer therapy in prostate tumors that express ErbB2.
|
23775445 |
2013 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Pharmacological inhibition of ErbB2 and c-Met reduced the ability of prostate tumor progenitor cells to undergo self-renewal in vitro.
|
23348745 |
2013 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In this study, we show that patients who develop prostate tumors with low levels of PTEN and high levels of HER2/3 have a poor prognosis.
|
21930937 |
2011 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis.
|
18767028 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.
|
18337451 |
2008 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Human epidermal growth factor receptor type 2 protein expression in Chinese metastatic prostate cancer patients correlates with cancer specific survival and increases after exposure to hormonal therapy.
|
18645672 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The subset of prostate tumors with increased HER-2/neu and AR levels may benefit from treatment strategies that target both signaling pathways.
|
18324648 |
2008 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
|
17363613 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In the sc implanted human prostate tumors (22Rv-1) in nude mice, AN-7 significantly inhibited Ki-67, HIF-1alpha, HER-2/neu, bFGF and increased PTEN level.
|
17611019 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Wwox suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling.
|
17704139 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Her2/neu expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients.
|
18038879 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
ErbB-2 via PYK2 upregulates the adhesive ability of androgen receptor-positive human prostate cancer cells.
|
17563746 |
2007 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A hypothetical protein H41 was detected, which may repress the Her-2/neu receptor influencing breast cancer, gliomas and prostate tumors.
|
17192923 |
2007 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
|
16984552 |
2006 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
|
16984552 |
2006 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Association of HER-2 polymorphism with Japanese sporadic prostate cancer susceptibility.
|
15389808 |
2005 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Of the 10 tumor samples analyzed by fluorescence in situ hybridization, genomic amplification of the Her-2/neu locus was not detected in any of the metastatic prostate tumors.
|
15269147 |
2004 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Peripheral blood lymphocytes (PBL) were then isolated from six consecutive human leukocyte antigen (HLA) A2+ patients with HER2/neu+ prostate tumors.
|
15547716 |
2004 |
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In order to define AR, erbB-1 and erbB-2 in human prostate neoplasms 36 benign prostatic hyperplasia, 46 prostatic carcinoma and 12 normal prostate gland samples were analysed.
|
14654929 |
2004 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia.
|
15083213 |
2004 |
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
The expression level was similar in all prostate tumor types and corresponded to the level of expression in breast carcinomas without ERBB2 amplification.
|
11786427 |
2002 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To quantitate the level of ERBB2 mRNA expression in prostate tumors (n = 34) and cell lines (n = 3), as well as in breast tumors (n = 30) and cell lines (n = 16), real-time reverse transcriptase-polymerase chain reaction (LightCycler) methodology was used.
|
11786427 |
2002 |
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Previous studies have reported widely divergent rates for HER2 expression in primary prostate tumors, probably owing to significant methodologic differences in the studies.
|
11488070 |
2001 |